Asset Details
Do you wish to reserve the book?
Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
Do you wish to request the book?
Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
2013
Overview
This phase 2 study assessed the safety, pharmacokinetics, pharmacodynamics and efficacy of carfilzomib, a selective proteasome inhibitor, in patients with multiple myeloma and varying degrees of renal impairment, including patients on chronic hemodialysis. Patients were grouped by creatinine clearance: >80 ml/min, 50–80 ml/min, 30–49 ml/min, <30 ml/min and chronic hemodialysis. Carfilzomib was administered on days 1, 2, 8, 9, 15 and 16 in 28-day cycles: 15 mg/m
2
(Cycle 1), 20 mg/m
2
(Cycle 2) and 27 mg/m
2
(Cycles 3+). There were no differences in carfilzomib clearance or exposure among patients with normal renal function and any group with renal impairment. Grade 3/4 adverse events (AEs) included anemia (28.0%), thrombocytopenia (20.0%), lymphopenia (18.0%) and fatigue (14.0%). AEs were similar among groups. At 15 mg/m
2
, proteasome inhibition up to 85% was observed and did not differ among groups. Although nearly 50% of patients were refractory to both bortezomib and lenalidomide, end of study partial response or better (overall response rate) was 25.5% with 7.9 months median duration of response. In conclusion, the pharmacokinetics and safety of carfilzomib were not influenced by the degree of baseline renal impairment, including in patients on dialysis, and carfilzomib was well tolerated and demonstrated promising efficacy.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Aged
/ Antineoplastic Agents - adverse effects
/ Antineoplastic Agents - pharmacokinetics
/ Antineoplastic Agents - therapeutic use
/ Blood
/ Complications and side effects
/ Female
/ Humans
/ Leukemia
/ Male
/ Medicine
/ Multiple Myeloma - complications
/ Multiple Myeloma - drug therapy
/ Oligopeptides - adverse effects
/ Oligopeptides - pharmacokinetics
/ Oligopeptides - therapeutic use
/ Oncology
/ Original
/ Proteasome Inhibitors - adverse effects
/ Proteasome Inhibitors - pharmacokinetics
/ Proteasome Inhibitors - therapeutic use
/ Renal Insufficiency - complications
/ Toxicity
